Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

S&P 500 Giants Meta, Eli Lilly Lead 5 Stocks Near Buy Points

Meta, Costco and Eli Lilly along with two others are trading near buy points coming out of a week marked by Nvidia earnings.

Investors Business Daily

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

Shares of mega-cap stocks such as Walmart, Meta Platforms, and Eli Lilly have surged over 40% in 2024, outpacing the broader markets by a wide margin.

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Eli Lilly Option Trade Could Return $1,650, If Stock Doesn't Go Haywire

The idea with the trade is that if Eli Lilly stock remains around 950 for the next few weeks, the sold option will decay faster than the bought option.

Investors Business Daily

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

International Business Times

Eli Lilly, An IBD 50 Stock, Nears Record High On Another Weight-Loss Win

Eli Lilly stock rose Tuesday after Lilly's weight-loss drug significantly cut the risk of developing diabetes over three years.

Investors Business Daily

Up 58% YTD, is Eli Lilly Stock Still a Buy?

The pharmaceutical giant has already delivered massive gains this year, but Wall Street analysts have only gotten more bullish on the maker of Mounjaro and Zepbound.

inkl

Read news from The Economist, FT, and more,
with one subscription

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review

Monday's global sell-off turned into a stock market rally attempt. Palantir, Eli Lilly and Fortinet were among the earnings winners.

Investors Business Daily

Eli Lilly Surges 10% After Diabetes, Weight-Loss Sales Wallop Expectations

Eli Lilly Surges 10% After Diabetes, Weight-Loss Sales Wallop Expectations

Eli Lilly stock rocketed Thursday after its diabetes and weight-loss drugs walloped expectations, leading to a guidance hike.

Investors Business Daily

1 Billionaire-Backed Penny Stock With 421% Upside

1 Billionaire-Backed Penny Stock With 421% Upside

Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.

How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut

How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut

Tirzepatide, a drug for diabetes and obesity, has sent the 148-year-old pharma giant on a wild ride. It’s now the ninth most valuable company in the world.

Should You Buy These Stocks Before They Join The $1 Trillion Market Cap Club?

Should You Buy These Stocks Before They Join The $1 Trillion Market Cap Club?

Their strong fundamentals, brand strength, and drive to succeed could propel their stock higher.

Jim Cramer Names Six Companies That May Enter the Trillion-Dollar Stock Club

Jim Cramer Names Six Companies That May Enter the Trillion-Dollar Stock Club

In a recent episode of CNBC's Mad Money show, Jim Cramer named companies like Eli Lilly, Tesla, JPMorgan, and Walmart that could reach a $1 trillion market valuation.

International Business Times UK

NBCU to Offer First-Ever Commercial-Free Hour During Live Coverage of the Olympics Opening Ceremony

NBCU to Offer First-Ever Commercial-Free Hour During Live Coverage of the Olympics Opening Ceremony

The commercial-free hour, which begins at 1:30 p.m. ET on July 26, is sponsored by Coke, Delta, Eli Lilly, Toyota, Visa, and Xfinity

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - US

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

Investors Business Daily

Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review

The stock market rally had some wild moves during the week. The Dow Jones and Russell 2000 jumped, but came off highs. The Nasdaq tumbled.

Investors Business Daily

Eli Lilly, Novo Nordisk — And Their Rivals — Skid On Roche's Weight-Loss Drug Results

Eli Lilly and Novo Nordisk fell Wednesday after Roche released positive early-stage trial data on its oral weight-loss drug.

The Independent UK

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Shares in Novo Nordisk were down 1.1% after the study

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic

Patients lost more significantly more weight on Eli Lilly's Mounjaro than Novo Nordisk's Ozempic, according to a new study.

The Independent UK

A weight loss miracle! New shot does better than Ozempic and Wegovy during trials

Tirzepatide, which is sold under the brand names Mounjaro and Zepbound – which treat diabetes and weight loss, respectively – leads to more weight loss than semaglutide, new research has shown

Investors Business Daily

Eli Lilly Snaps Up Morphic For $3.2 Billion; Morphic Stock Hits The Stratosphere

Eli Lilly said Monday it would acquire Morphic Holding for $3.2 billion, and Morphic stock skyrocketed to a 10-month high.

What Is Kisunla? Know All About New FDA-Approved Drug For Alzheimer's Disease

Kisunla manufactured by Eli Lilly could significantly slow cognitive decline in people with early symptomatic Alzheimer's disease, according to results of the company's clinical trials.

FDA Approves New Alzheimer's Drug To Slow Disease Progression

FDA approves Eli Lilly's donanemab for early Alzheimer's, offering hope for patients and caregivers. Treatment priced at 5 per vial.

The Guardian - US

FDA approves second Alzheimer’s drug that can slow onset of disease

Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease

Investors Business Daily

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug

Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.

People

100,429 stories

Mark Zuckerberg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Associated Press

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

253,284 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play